New Drug Targets Deadly Lung Scarring Disease With Phase 2 Trial Fully Enrolled
Calluna Pharma's CAL101 monoclonal antibody enters Phase 2 testing for IPF, a fatal lung disease with only 3–5 year median survival.
Summary
Calluna Pharma has completed enrollment in its Phase 2 AURORA trial testing CAL101, a monoclonal antibody designed to slow idiopathic pulmonary fibrosis — a progressive lung scarring disease with no cure and a median survival of just 3 to 5 years. The trial enrolled 161 patients across more than 50 sites in the US, UK, EU, Turkey, and South Korea, finishing enrollment over six months ahead of schedule. CAL101 targets a damage-associated protein called S100A4, which plays a role in fibrosis development. The drug is given monthly via intravenous infusion, and the trial will measure changes in lung function over six months. Topline results are expected in early 2027.
Detailed Summary
Idiopathic pulmonary fibrosis is one of the most aggressive age-related lung diseases, causing progressive scarring that steadily destroys breathing capacity. With a median survival of just three to five years after diagnosis and approximately 233,000 patients affected across the US and EU, effective treatments remain a critical unmet need. Calluna Pharma's Phase 2 AURORA trial represents a meaningful step toward a novel therapeutic approach.
CAL101 is a monoclonal antibody administered intravenously that targets S100A4, a damage-associated molecular pattern protein implicated in fibrotic signaling. By blocking S100A4, the drug aims to interrupt the scarring cascade that progressively stiffens and destroys lung tissue. Preclinical studies reportedly showed both prevention and reversal of fibrosis, and a Phase 1 trial demonstrated a favorable safety profile with predictable drug behavior in the body.
The AURORA study enrolled 161 adults across more than 50 global sites in a randomized, double-blind, placebo-controlled design — the gold standard for clinical evidence. Patients receive monthly intravenous infusions of CAL101 or placebo for six months following a 28-day screening window. The primary endpoint is change from baseline in forced vital capacity, a standard and clinically meaningful measure of lung function decline in IPF.
Enrollment was completed more than six months ahead of schedule, suggesting strong investigator and patient interest. Topline data are anticipated in the first quarter of 2027, which could position CAL101 for accelerated regulatory discussions if results are positive.
For longevity-focused readers, IPF is a stark example of age-accelerated tissue fibrosis — a process also implicated in heart, kidney, and liver aging. Therapies that successfully target fibrotic pathways like S100A4 could have broader implications beyond the lungs. However, Phase 2 trials frequently fail to replicate preclinical promise, and results remain pending.
Key Findings
- CAL101 targets S100A4, a protein driving lung scarring in IPF, a disease with 3–5 year median survival.
- Phase 2 AURORA trial enrolled 161 patients across 50+ global sites, finishing 6 months ahead of schedule.
- Primary endpoint measures forced vital capacity change — a direct, clinically meaningful lung function metric.
- Phase 1 data showed favorable safety and predictable pharmacokinetics before advancing to Phase 2.
- Topline efficacy results expected Q1 2027, with potential implications for broader anti-fibrotic therapies.
Methodology
This is a news report summarizing a company press release about trial enrollment completion. The source, Longevity.Technology, is a credible longevity-focused outlet, but the evidence basis is industry-reported Phase 1 data and preclinical findings, not yet peer-reviewed Phase 2 results.
Study Limitations
No Phase 2 efficacy data are yet available; all positive signals come from preclinical work and a Phase 1 safety study. Company-reported timelines and outcomes should be verified against peer-reviewed publications and ClinicalTrials.gov when available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.